CytRx initiates Phase 1b trial with combination Aldoxorubicin, Doxorubicin
CytRx initiates Phase 1b trial with combination Aldoxorubicin, Doxorubicin The Fly on the Wall
View ArticlePreliminary Phase 1 Data for Cabozantinib in Japanese Patients Presented at...
Preliminary Phase 1 Data for Cabozantinib in Japanese Patients Presented at ESMO 2012 Yahoo/BusinessWire
View ArticleInnate Pharma: Phase I Clinical Trial of IPH2102/BMS-986015 in Combination...
Innate Pharma: Phase I Clinical Trial of IPH2102/BMS-986015 in Combination With Ipilimumab Announced Yahoo
View ArticleNorthwest Biotherapeutics: An Example Of Reform In The Drug Approval Process
Northwest Biotherapeutics: An Example Of Reform In The Drug Approval Process Seeking Alpha
View ArticleIllumina Launches TruSight™ Tumor Content Set
Illumina Launches TruSight™ Tumor Content Set Yahoo
View ArticleBioMarin abstract showed impressive anti-tumor activity, says Leerink
BioMarin abstract showed impressive anti-tumor activity, says Leerink Yahoo/Fly on the Wall
View Article3 Small Cap Cancer Stocks With Upcoming Catalysts
3 Small Cap Cancer Stocks With Upcoming Catalysts Seeking Alpha
View ArticleCytRx announces data from Phase 1b trial of aldoxorubicin
CytRx announces data from Phase 1b trial of aldoxorubicin Yahoo/Fly on the Wall
View ArticleImmunomedics Advances Solid Tumor Antibody-Drug Conjugate Programs to Phase...
Immunomedics Advances Solid Tumor Antibody-Drug Conjugate Programs to Phase II Clinical Trials Yahoo
View ArticleOngoing Phase I Monotherapy Study of Rucaparib in Patients with Solid Tumors...
Ongoing Phase I Monotherapy Study of Rucaparib in Patients with Solid Tumors Demonstrates Clinical Activity, Establishes Dose and Schedule Yahoo/BusinessWire
View ArticleOncoMed Pharmaceuticals Presents Updated Phase 1a Data in Advanced Solid...
OncoMed Pharmaceuticals Presents Updated Phase 1a Data in Advanced Solid Tumor Patients for the First-in-Class WNT-Pathway-Targeting Antibody Vantictumab (OMP-18R5) at the European Cancer Congress 2013...
View ArticleFive Data Presentations on BioMarin's BMN 673 PARP Inhibitor at the 2013...
Five Data Presentations on BioMarin's BMN 673 PARP Inhibitor at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Yahoo/Globe Newswire
View ArticleImmunomedics announces IMMU-132 is active in patients refractory to Irinotecan
Immunomedics announces IMMU-132 is active in patients refractory to Irinotecan Yahoo/
View ArticleBaxter, Cell Therapeutics announce collaboration to develop pacritinib
Baxter, Cell Therapeutics announce collaboration to develop pacritinib Yahoo/Fly on the Wall
View ArticleIf Northwest Biotherapeutics Wins, It Wins Big
If Northwest Biotherapeutics Wins, It Wins Big Seeking Alpha
View Article
